Breadcrumb
[G14-07] Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Overview
Overview
| Commission: | Commission awarded on 2014-07-22 by the Federal Joint Committee (G-BA) |
|---|---|
| Status: | Commission completed |
| Department/Division: | Health Economics |
| Current document: | 
Dossier assessment
(German version)
Further documents |
| Note: | In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Cabozantinib report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier. |
| Contact address: | to the contact form |
| Linked projects: |
[A18-85]
Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed [A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Status: Commission completed [A16-69] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Status: Commission completed |
Report documents
Report documents
| Published | Document | Size | Type | |
|---|---|---|---|---|
| 2014-11-03 | Dossier assessment (German version) | 137 kB |  |
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information
Federal Joint Committee (G-BA)
2015-01-22 A G-BA decision was published.
G-BA documents on this decision
